Tempest Therapeutics
TPST
45 hedge funds and large institutions have $120M invested in Tempest Therapeutics in 2014 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 3 reducing their positions, and 3 closing their positions.
633% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 3
300% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 3
62% more capital invested
Capital invested by funds: $73.9M → $120M (+$45.7M)
25% more funds holding
Funds holding: 36 → 45 (+9)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$12.7M |
| 2 |
DM
Deerfield Management
New York
|
+$10.3M |
| 3 |
Jennison Associates
New York
|
+$6.89M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.85M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$3.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$2.06M |
| 2 |
BCM
BBT Capital Management
Fort Worth,
Texas
|
-$794K |
| 3 |
LOM
Loeb Offshore Management
New York
|
-$161K |
| 4 |
FTUS
Flow Traders U.S.
New York
|
-$150K |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$28.3K |
TPST Hedge Fund Activity: Q1 2014 in Review
45 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q1 2014, worth a combined $120M — up 62% from $73.9M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new TPST positions and 3 closed out — a net gain of 9 holders — while 22 added to existing stakes and 3 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $12.7M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $2.06M sold.
- 45 institutional investors held Tempest Therapeutics (TPST) as of Q1 2014, up from 36 in Q4 2013.
- Funds reported $120M of Tempest Therapeutics stock for Q1 2014, up 62% quarter-over-quarter.
- 12 funds opened new Tempest Therapeutics positions in Q1 2014 and 3 closed out, a net change of +9 holders.
- The largest Tempest Therapeutics buyer in Q1 2014 was Adage Capital Partners, an estimated $12.7M added.
- The largest Tempest Therapeutics seller in Q1 2014 was JP Morgan Chase, an estimated $2.06M sold.
Based on aggregated 13F filings for Q1 2014.